Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shenogen Signs Up ShangPharma to Help Develop Cancer Drug

publication date: Mar 16, 2011
Shenogen Pharma, a company developing mAbs that target the ER-alpha 36 receptor to treat cancer, has signed a contract with ShangPharma Corporation for development work. The emphasis on mAbs represents a departure for Shenogen, which previously sought to blend Western pharma with its knowledge of TCM. The company’s lead molecule, SNG-162, is a TCM that targets an Estrogen Receptor (ER) variant discovered by one of Shenogen’s founders. Shenogen Pharma’s science was so impressive it won a “Most Promising Company” award at the Shanghai ChinaBio® Investor Forum held in 2008. More details....

Stock Symbol: (NYSE: SHP)     Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital